Connect with us

Business

How CV Sciences Inc (OTCMKTS:CVSI) Has Battled Back Against the Bears

Published

on

CV Sciences Inc (OTCMKTS:CVSI) provides an excellent case study in understanding market forces at work. The company is arguably one of the most impressive growth stories in the CBD space, and the company’s recent earnings data continue to exemplify this trend. However, bears have attacked the company, led by Andrew Left’s Citron Research, who put out some research on the company back in August that suggested improper messaging around a patent application.

However, that narrative doesn’t detract from the sales growth trend in play. To further drive home that point, the company just announced Record Sales of $13,600,000, an increase of 143% compared to Q3 2017, Record Gross Profit of $9,945,000, an increase of 149% compared to Q3 2017, Record GAAP Net Income of $3,295,000, an improvement of $3,885,000 compared to Q3 2017, and Record Adjusted EBITDA of $4,128,000, an improvement of $3,253,000 compared to Q3 2017.

CV Sciences Inc (OTCMKTS:CVSI) bills itself as a company that operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.

Moreover, CV Sciences, Inc. operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.

The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.

CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.

 

Moving Ahead

“We are encouraged by our performance as we delivered another strong quarter, including our third consecutive quarter of profitability. This was led by initiatives that include accelerating our brand recognition and brand loyalty and growing sales distribution channels that have generated triple-digit year-over-year revenue growth and double-digit sales growth on a sequential quarterly comparison. The demand continues to respond strongly to our leading PlusCBD™ product line, #1 in the hemp CBD product category in the natural products retail channel and we believe this is just the beginning for the vast and nascent hemp CBD market. Most notably during the quarter, we earned the industry’s first self-affirmed Generally Recognized as Safe (GRAS) status for our Gold Formula product line, a move that shows our dedication to building consumer confidence, trust and safety of our products. In conjunction with that, our product innovation was on full display with the introduction of our new PlusCBD Oil™ Gummies in two flavors, Cherry Mango and Citrus Punch as additional factors for driving revenue,” stated Joseph Dowling, Chief Executive Officer of CV Sciences.

CV Sciences Inc (OTCMKTS:CVSI) pulled in sales of $13.6M in its last reported quarterly financials, representing top line growth of 143.3%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($11M against $3M).

Mr. Dowling added, “Our drug development program is making steady progress in advancing our proprietary lead drug candidate – CVSI-007 – which addresses the multibillion dollar smokeless tobacco use and addiction market. We continue to make progress with our pre-clinical program, anticipating filing an Investigational New Drug application in 2019.  We are confident that our continued growth and profitability will allow us to initially pursue our drug development plans without the need for additional outside capital in the near term. Given the industry’s robust growth momentum, we believe we have the right strategies in place and remain committed to achieve a strong 2018 finish.”

Business

Singlepoint Inc. (OTCMKTS: SING) In A Joint Venture With Box Biosciences To Produce and Distribute Hand Sanitizers

Published

on

Singlepoint Inc. (OTCMKTS:SING) has formed a joint venture with BOX Biosciences to distribute various hand-sanitizer products produced in Carlsbad, California.

Singlepoint joint venture producing FDA-approved sanitizer

The two companies are distributing the FDA-approved sanitizer products on the west and east coast. BOX Biosciences is headquartered in Charleston, South Carolina, with distribution outlets in Raleigh, North Carolina, and Carlsbad, California. Following the coronavirus outbreak, there has been a shortage of disinfectant and sanitizer products.

Because of the urgent need to fill this shortage, the companies through the joint venture are working to ensure the US is safe by producing bulk hand sanitizers. They will also introduce disinfectants as permitted by the demand of hand sanitizers. Already the companies have on-going sales to various retail outlets, and currently, they are in discussions for potential hand sanitizer product sales.

The sanitizers the companies are manufacturing kill 99.9% of coronavirus causing germs, and they will be available to the general public and essential businesses. For now, the companies have prioritized the sanitizers to nursing homes, clinics, hospitals, government units, and home healthcare agencies. Equally essential businesses will also get prioritized in getting the bulk hand sanitizers.

Singlepoint and Box committed to offering solutions to COVID-19

Ryan Cowell, the founder of BOX Biosciences, indicated that they will focus on bulk orders of 250 gallons, 55-gallon drums, 1 gallon, 1 liter, 32oz, and 8oz totes of sanitizer. For businesses having the ability to offload bulk sanitizer from tankers, they can also order.

Singlepoint and Box’s expansion to making disinfectant and hand sanitizers shows how companies are dedicated to offering significant well-being solutions for the environment, surfaces, and people in response to the COVID-19 outbreak.

BOX’s operations manager Troy Lorenz stated there is an urge by businesses and people to clean and disinfect their work environment, and as a result, the products they are producing are important for the environment and people. The objective of Singlepoint and Box is to help authorities and people in combating the spread of COVID-19.

Continue Reading

Business

Sproutly Canada Inc (OTCMKTS:SRUTF) Chalks Out A Business Strategy To Focus On Commercialization Of APP Technology

Published

on

Sproutly Canada Inc (OTCMKTS:SRUTF) has chalked out a business transformation strategy to focus on commercializing its proprietary APP technology by moving away from cannabis cultivation resources. Infusion Biosciences Inc will contribute additional funds to implement business transformation. It will also supply additional talent to support the transformation plan.

Business transformation strategy

As part of the light technology model, Sproutly will focus on generating revenues through establishing ingredient supply agreements, technology licensing, and partnership opportunities. It will scale down the cultivation of cannabis, which is capital intensive, and reduce cash burn.

Sproutly has recruited Dr. Anup Sen as Chief Executive Officer for implementing a business transformation plan. Anup is the first scientist to invent water soluble CBD in cannabis plants. Following the appointment of Dr. Anup, Keith Dolo is relinquishing the post of CEO. Keith will also step down from the board of Sproutly. He will act as an advisor to the Chairman. Keith said the company’s main target is to introduce unique products in the market by using APP Technology. Sproutly also slashed cash expenses by giving pink slips to operational and corporate staff.

Sproutly is adopting the new business strategy because of the operational challenges and headwinds in the industry. Prohibitive costs associated with cannabis cultivation have forced the company to change its business strategy.

Commercializes APP technology

Sproutly will focus on APP technology commercialization through formulation, production, and the sale of ingredients by using Bi-Natural Oils and water-soluble cannabinoids. The company will use the licensed manufacturers’ distribution networks and its existing infrastructure to realize its revised plan. Sproutly has faced bottlenecks in introducing cannabis 2.0 products because it has earmarked human resources and significant capital for cannabis cultivation.

Adopts cost-cutting measures

Sproutly has reduced the employees by 75% to reduce costs and reduce cannabis cultivation. It has eased the capital requirements for Sproutly and pursues other strategic alternatives. The company will get the support of six key personnel of Infusion Biosciences to assist in its daily operations.

Infusion Biosciences’s key executives have helped Sproutly in obtaining licenses for APP technology and in forming partnerships in the US. Sproutly also expects to expedite its commercialization efforts with the help of these executives.

Continue Reading

Business

Aleafia Health Inc (OTCMKTS:ALEAF) Reports An Astonishing 2,486% Rise In Q1 2020 Revenues

Published

on

Aleafia Health Inc (OTCMKTS:ALEAF) has reported revenues of $14.59 million in Q1 2020. It is an increase of 2,486% compared to the same period last year and a 143% increase compared to the previous quarter.

Reports solid growth for the fifth consecutive quarter

Geoffrey Benic, Chief Executive Officer of Aleafia, said the company achieved a breakthrough in Q1 2020 on the backdrop of sustainable and disciplined growth. As it builds the cannabis wellness and health ecosystem, the company gives importance to the patient-centric approach. It is the fifth consecutive quarter to report solid growth.

Expects to introduce new cannabis 2.0 products in H2

Aleafia expects to introduce new cannabis 2.0 products tailored for the wellness and health consumers in H2, 2020. Its active registered patient count has surged to 10,983 as of March 31, 2020, from 10,249 as of December 31, 2019.

Key achievements in Q1 2020

Aleafia on March 26, 2020, announced plans to introduce direct-to-door medical cannabis delivery service to the registered patients. It is a contactless and safe delivery mechanism for the patients. Therefore, Aleafia eliminates the need for collecting the products from post boxes and post offices.

Achievements after Q1 2020

According to the announcement on May 1, 2020, Glenn Washer and Rhonda Lawson will be appointed to the board with effect from May 16, 2020. It is on the backdrop of the resignation of the existing directors – Bill Stewart, and Raf Souccar with effective from May 15, 2020. Julian Fantino, Chairman, has also resigned from the board.

Aleafia has temporarily shut down its physical offices of the education centers and cannabis clinics across the nation since March 16, 2020, because of the ongoing coronavirus crisis. The company is completing the patient consultations via its virtual clinics.

To maintain long term success, the company maintains a diversified portfolio of differentiated and high-quality product formats. The company will use in-house facilities to manufacture cannabis 2.0 products and satisfy the demand in the medical and adult-use cannabis markets in Canada. It will also supply cannabis 2.0 products in markets worldwide where legally permitted.

Aleafia Farms Inc, a wholly-owned subsidiary of Aleafia, has secured an amended license from Health Canada on May 12, 2020, for the outdoor cultivation at its Port Perry Facility.

Continue Reading
Advertisement

Whats Hot